Skip to main content
See every side of every news story
Published loading...Updated

Stem cell therapy frees diabetics from insulin

UNITED STATES, JUN 21 – Zimislecel, a stem cell therapy, enabled 83% of severe type 1 diabetes patients to stop insulin injections for at least one year, with no severe hypoglycemia reported, researchers said.

  • Vertex Pharmaceuticals presented phase 2 FORWARD study results on June 20-23, 2025, showing that 10 of 12 type 1 diabetes patients became insulin independent after receiving zimislecel in Chicago.
  • The results followed more than 25 years of research, with patients receiving a portal vein infusion of stem cell-derived islet cells plus immunosuppressive drugs to prevent immune rejection.
  • All 12 participants showed islet cell engraftment with C-peptide detected after infusion, maintained healthy glucose levels, avoided severe hypoglycemia, and 10 stopped insulin use after about six months.
  • Michael Rickels expressed optimism that the results could lead to a groundbreaking therapy, while Marlon Pragnell highlighted stem cell treatment as a highly encouraging development that could significantly improve management of type 1 diabetes.
  • The study’s success may lead to a regulatory submission next year and suggests a potential new treatment to restore insulin production and reduce hypoglycemia risks in type 1 diabetes patients.
Insights by Ground AI
Does this summary seem wrong?
Podcasts & Opinions

73 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 58% of the sources are Center
58% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Globe & Mail broke the news in Canada on Friday, June 20, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal